Quarterly report pursuant to Section 13 or 15(d)

Note 8 - Accrued Liabilities

v3.23.1
Note 8 - Accrued Liabilities
3 Months Ended
Mar. 31, 2023
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

8.

Accrued Liabilities

 

Accrued liabilities consisted of the following (in thousands):

 

   

March 31, 2023

   

December 31, 2022

 

Accrued compensation

  $ 161     $ 667  

Accrued clinical trial costs

    376       472  

Accrued research and other professional fees

    414       215  

Accrued other liabilities

    5       11  

Total accrued liabilities

  $ 956     $ 1,365